Xeris Biopharma (NASDAQ:XERS – Get Free Report) and Cocrystal Pharma (NASDAQ:COCP – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.
Institutional and Insider Ownership
42.7% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 4.3% of Xeris Biopharma shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk & Volatility
Xeris Biopharma has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500.
Valuation and Earnings
This table compares Xeris Biopharma and Cocrystal Pharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $291.85 million | 6.69 | $550,000.00 | ($0.11) | -97.36 |
| Cocrystal Pharma | $330,000.00 | 58.08 | -$8.83 million | ($0.76) | -1.31 |
Xeris Biopharma has higher revenue and earnings than Cocrystal Pharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than Cocrystal Pharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Xeris Biopharma and Cocrystal Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | -5.12% | 338.21% | 3.50% |
| Cocrystal Pharma | N/A | -207.47% | -123.33% |
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Xeris Biopharma and Cocrystal Pharma, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 1 | 1 | 4 | 0 | 2.50 |
| Cocrystal Pharma | 1 | 0 | 1 | 0 | 2.00 |
Xeris Biopharma presently has a consensus target price of $13.20, indicating a potential upside of 23.25%. Given Xeris Biopharma’s stronger consensus rating and higher probable upside, equities analysts clearly believe Xeris Biopharma is more favorable than Cocrystal Pharma.
Summary
Xeris Biopharma beats Cocrystal Pharma on 9 of the 14 factors compared between the two stocks.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About Cocrystal Pharma
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
